Filing Details
- Accession Number:
- 0001746473-24-000005
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-19 17:19:32
- Reporting Period:
- 2024-01-17
- Accepted Time:
- 2024-01-19 17:19:32
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1746473 | Pliant Therapeutics Inc. | PLRX | Pharmaceutical Preparations (2834) | 474272481 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1809204 | Lamont Keith Cummings | C/O Pliant Therapeutics, Inc. 260 Littlefield Avenue South San Francisco CA 94080 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-01-17 | 9,781 | $17.23 | 194,605 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive, between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
- Includes 387 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.